410
Participants
Start Date
March 31, 2010
Primary Completion Date
August 25, 2016
Study Completion Date
August 25, 2016
BIIB019 (Daclizumab)
Administered as specified in the treatment arm.
trivalent seasonal influenza vaccine
All participants who participate in the 2013-2014 influenza vaccine substudy will receive the vaccine at the study site
Research Site, Budapest
Research Site, Budapest
Research Site, Budapest
Research Site, Budapest
Research Site, Budapest
Research Site, Kiev
Research Site, Esztergom
Research Site, Miskolc
Research Site, Miskolc
Research Site, Debrecen
Research Site, Nyíregyháza
Research Site, Kecskemét
Research Site, Siófok
Research Site, Győr
Research Site, Rostock
Research Site, Lublin
Research Site, Marburg
Research Site, Poltava
Research Site, Dnipropetrovsk
Research Site, Chernivtsi
Research Site, Kharkiv
Research Site, Zaporizhia
Research Site, Zaporizhia
Research Site, Donetsk
Research Site, Erlangen
Research Site, Bayreuth
Research Site, Moscow
Research Site, Moscow
Research Site, Yaroskavi
Research Site, Saint Petersburg
Research Site, Smolensk
Research Site, Rajasthan
Research Site, Mumbai
Research Site, Kazan'
Research Site, Samara
Research Site, Ufa
Research Site, Hyderabad
Research Site, Bangalore
Research Site, Nizhny Novgorod
Research Site, Novosibirsk
Research Site, Omsk
Research Site, Krasnoyarsk
Research Site, Kolkata
Research Site, Moscow
Research Site, Brno
Research Site, Brno
Research Site, Hradec Králové
Research Site, Prague
Research Site, Teplice
Research Site, Bialystok
Research Site, Bialystok
Research Site, Gdansk
Research Site, Katowice
Research Site, Katowice
Research Site, Krakow
Research Site, Lodz
Research Site, Warsaw
Research Site, Warsaw
Research Site, Kiev
Research Site, Kyiv
Research Site, London
Research Site, Nottingham
Research Site, Plymouth
Research Site, Sheffield
Research Site, Stoke-on-Trent